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Abstract
Background: Currently 1 in 11 women over the age of 60 in Australia are diagnosed with breast
cancer. Following treatment, most breast cancer patients are left with shoulder and arm
impairments which can impact significantly on quality of life and interfere substantially with activities
of daily living. The primary aim of the proposed study is to determine whether upper limb
impairments can be prevented by undertaking an exercise program of prolonged stretching and
resistance training, commencing soon after surgery.
Methods/design: We will recruit 180 women who have had surgery for early stage breast cancer
to a multicenter single-blind randomized controlled trial. At 4 weeks post surgery, women will be
randomly assigned to either an exercise group or a usual care (control) group. Women allocated
to the exercise group will perform exercises daily, and will be supervised once a week for 8 weeks.
At the end of the 8 weeks, women will be given a home-based training program to continue
indefinitely. Women in the usual care group will receive the same care as is now typically provided,
i.e. a visit by the physiotherapist and occupational therapist while an inpatient, and receipt of
pamphlets. All subjects will be assessed at baseline, 8 weeks, and 6 months later. The primary
measure is arm symptoms, derived from a breast cancer specific questionnaire (BR23). In addition,
range of motion, strength, swelling, pain and quality of life will be assessed.
Discussion: This study will determine whether exercise commencing soon after surgery can
prevent secondary problems associated with treatment of breast cancer, and will thus provide the
basis for successful rehabilitation and reduction in ongoing problems and health care use.
Additionally, it will identify whether strengthening exercises reduce the incidence of arm swelling.
Trial Registration: The protocol for this study is registered with the Australian Clinical Trials
Registry (ACTRN012606000050550).
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Background
Upper limb arm morbidity resulting from treatment for
early breast cancer is a common sequela of treatment for
breast cancer [1]. In a study of 644 older women treated
for breast cancer, 54% reported a decline in upper body
function compared to 10% in the control group who had
not undergone treatment [2]. Based on reports of upper
limb morbidity [2], current practices do not adequately
address or prevent the impairments that may arise from
management of the tumour. While the long-term morbid-
ity is well documented, little evidence is available to
inform clinicians in the best way to minimise and prevent
these upper limb problems. As upper limb morbidity is
associated with reduced quality of life [3,4], particularly
emotional, social and physical functioning aspects, as
well as body image and lifestyle [5], it is important that
effective preventive strategies be identified.
The potential benefits of progressive resistance training
soon after surgery has not been investigated even though
many women report shoulder weakness [4,6-8]. It is com-
monly believed that vigorous arm exercises will induce
lymphedema [9] although evidence from our pilot study
challenges this belief [10]. To date, no studies have inves-
tigated the use of resistance training early after surgery,
although this may be the stage at which exercises have the
greatest effect in preventing lymphedema and muscle
weakness.
Stretching is advocated following breast cancer surgery;
however, given the reports of reduced range and conse-
quent shoulder stiffness [4,6-8,11], the stretching proto-
cols do not appear to have been performed in a
particularly effective way. Little detail of the actual exer-
cises has been provided in the available randomized con-
trolled trials [12]. In several studies, participants were
seen by a physiotherapist but details of the exercises,
including duration, were omitted [12]. Evidence from ani-
mal models suggests that adverse physiological adapta-
tions can be prevented with prolonged daily stretching
[13] and prolonged stretches at the shoulder have been
shown to be highly effective in other patient populations
at risk of developing significant loss of range [14]. Thus,
prolonged stretches may decrease the loss of range and
joint stiffness consequent to treatment for breast cancer.
We therefore aim to conduct a randomized controlled
trial to determine whether an intensive exercise program,
commencing 4 weeks after breast cancer surgery, prevents
weakness, pain, swelling, and loss of range in the upper
limb. We will also determine whether quality of life (as
measured by arm symptoms) improves for women who
undertake an intensive exercise program early after breast
cancer surgery. Lastly, we will determine the effect of
resistance training soon after surgery on the short-term
occurrence of lymphedema.
Methods/design
Design
To determine the efficacy of an intensive upper limb exer-
cise program for women soon after breast cancer surgery,
we will conduct a multi-center, single-blind randomised
controlled trial. Women will be recruited from 3 large
hospitals with breast cancer oncology services in Sydney,
Australia. Breast Cancer Nurses will inform potential par-
ticipants about the study when they visit the patient after
surgery. To provide sufficient time for the wound to heal,
women will enter the study 4 weeks after surgery.
A record will be kept of the number of invitations to par-
ticipate, the number of potential participants who volun-
teer to participate, and the number of screened patients
who are ineligible and the reason for their ineligibility.
Ethical approval has been received from the participating
hospitals as well as from The University of Sydney. All par-
ticipants will provide written informed consent.
Participants
Women will be included in the study if they: have under-
gone a breast cancer intervention that included surgery to
the axilla; can attend for treatment and follow-up; under-
stand English and consent to participate and be ran-
domised to either treatment group. Women scheduled for
adjunct treatments including radiotherapy, chemotherapy
and breast reconstruction will be included.
Women will be excluded if they have not had surgery to
the axilla or have undergone bilateral operations, present
with infection at the baseline measurement or have
received previous treatment for breast cancer or have met-
astatic disease. In addition, women will be excluded if
they have sustained a fracture, undergone surgery in the
upper limbs, or suffered any neurological deficit or other
injury to either upper limb that may interfere with the test
procedures. Lastly, women will be excluded if they
undergo breast reconstruction and as a consequence, their
specialist has indicated that they are not to participate.
Randomization
An investigator who has no direct contact with the sub-
jects will be responsible for generating the randomisation
list. Randomisation will be stratified by whether women
receive axillary node resection or sentinel node biopsy.
The randomisation list will be used to prepare numbered
opaque envelopes with the group allocation sealed inside
by a person not involved in the study. Immediately after
baseline assessment, women will be randomly allocated
to either the usual care or exercise group. The protocol forBMC Cancer 2006, 6:273 http://www.biomedcentral.com/1471-2407/6/273
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this study is registered with the Australian Clinical Trials
Registry (ACTRN012606000050550).
Interventions
Usual care
Women will receive the same care as is now provided in
the three participating hospitals. Women are typically
admitted on the day of surgery and are discharged 2 to 7
days after surgery. While in hospital, they are seen by a
physiotherapist who reviews gentle shoulder exercises
which are outlined in a pamphlet. The active assisted
shoulder exercises are for shoulder protraction, elevation
and abduction. In addition, women are seen by an occu-
pational therapist who discusses issues related to preven-
tion of lymphedema. Women are not followed by either
the physiotherapist or the occupational therapist after dis-
charge from the hospital.
Women in the Usual Care group will not be given a home
program of exercises, apart from those described in the
pamphlet. To control for attention from the research
assistant, they will meet with the research assistant fort-
nightly at which time their arm will be assessed with mul-
tifrequency bioimpedance analysis [15] for the
development of lymphedema, but no specific advice will
be given about exercise and management.
Exercise group
Commencing Week 4 following surgery, women will
attend 8 weekly exercise sessions comprising stretching
exercises and resistance training, and will commence a
daily home program of similar exercises. We have used
these exercises in our pilot study [10], and they are well
tolerated.
Each week, there will be a supervised weekly session at
which women will perform the shoulder exercises target-
ing the muscles and shoulder movements likely to be at
risk. Stretches will consist of prolonged holds of at least 5
minutes duration. The stretches are performed in supine
and are undertaken for the shoulder extensors, and for
pectoralis major and minor muscles. For women unable
to achieve >90 deg forward flexion, shoulder extension
and abduction stretches will be performed whilst seated.
For both stretches, the arm will be elevated in the appro-
priate direction and supported on pillows; the aim of
these stretches is to provide a comfortable stretch in the
region of the participant's axilla. Each of these stretches
will also be held initially for 5 minutes and progressed up
to 20 min. Once shoulder flexion >90 deg is achieved, the
participant will undertake the stretches in supine. The
muscles targeted for resistance training include the shoul-
der flexors, abductors, external rotators and horizontal
flexors. For strength training, the resistance will be deter-
mined by the Borg Effort Scale [16] and provided by free
weights. Each week, the exercises will be monitored, and
progressed as required.
In addition to the weekly supervised sessions, women will
perform a daily home program. The program will consist
of i) a daily stretching program and ii) a strengthening
program undertaken on alternate days. The stretching pro-
gram will be the same as that undertaken at the weekly
supervised session. For the strengthening program, the
same muscles will be trained as in the weekly supervised
sessions but rather than free weights, the resistance will be
provided by theraband. Participants will be instructed to
perform two sets of 8 – 12 repetitions for each exercise.
Participants will be instructed to work at a target of 15
('Hard') on the Borg Effort Scale [16]
At the conclusion of the program, women will be encour-
aged to continue the home program. A compliance diary
will be provided to record the number of times each exer-
cise was performed each day. In addition, women in both
groups will be asked to record any other treatments that
they have received the dose, and the effect.
Measurement
All measurements will be undertaken by a research assist-
ant blinded to the group to which women were allocated.
Variables will be measured before randomization, at 8
weeks (the end of the intervention phase) and then at 6
months to determine the effect of the intervention on
physical and psychosocial outcomes. In addition, infor-
mation about the breast cancer treatment regimen,
pathology report, age, weight, and previous shoulder
pathology will be obtained from the patient's medical
record at the baseline assessment. Occurrence of side-
effects and adverse events will be evaluated at each meas-
urement occasion.
The primary outcome measure for treatment efficacy is
arm symptoms on the operated side, derived from 3 items
of the Breast Module (BR23). The BR23 is a 23-item sur-
vey specific to women with breast cancer. The 3 selected
items ask whether in the past week the woman has had
pain in her arm or shoulder, a swollen arm or hand, and
whether it was difficult to raise or move her arm sideways.
For each question, there are 4 possible responses, ranging
from 'not at all' to 'very much'. The raw scores for these
questions are summed and then subjected to linear trans-
formation to provide an overall score, with a maximum of
100. A high score indicates a high level of symptoms. The
primary endpoint for the trial is change in primary out-
come from baseline to 6 months.
Secondary outcomes include other aspects of quality of
life and measures of physical impairment.BMC Cancer 2006, 6:273 http://www.biomedcentral.com/1471-2407/6/273
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Quality of life will be measured using the European
Organisation for Research and Treatment of Cancer Qual-
ity of Life Questionnaire Version 3 (QLQ-C30) and the
Breast Module (BR23). These surveys are specific to cancer
patients and comprise a global health status/quality of life
scale, as well as functional and symptom scales. These
questionnaires are reliable, valid and sensitive to change
and able to distinguish patients in different disease stages
and with different performance status [17-19].
Shoulder range of motion will be assessed using an incli-
nometer and a standardised protocol will be followed to
minimise compensatory movements. Passive forward
flexion, external rotation and horizontal abduction at the
shoulder will be assessed in a supine position and with
gravity as the standardised force. Active abduction will be
assessed in the sitting position. Each arm will be measured
separately. Pain at the end of the passive range of each
movement will be measured using a standardised 10 cm
visual analogue scale.
Maximal isometric shoulder strength will be measured
objectively with a dynamometer using a standardised pro-
tocol. The arm will be positioned at 90 degrees elevation
to assess forward flexion, abduction, and horizontal
abduction and adduction. Movement in these planes has
been selected as it has been shown to be weak following
breast cancer surgery [20,21]. For each direction, women
will perform 3 maximum voluntary contractions, and the
highest of the three attempts will be recorded. Each arm
will be measured separately.
The presence of lymphedema will be measured non-inva-
sively using multiple frequency bio-impedance analysis.
This analysis identifies early changes in tissue fluid accu-
mulation [22] and is substantially more sensitive than
total limb volume measurements in detecting changes in
extracellular fluid volume. It has an extremely low (<1 %)
false-positive rate for detecting lymphedema [22]. In addi-
tion, circumference measures at multiple sites on each
arm will be obtained using a standardised measurement
technique.
All women will be requested to record use of resources
(number and type of health care contacts, medication use,
adjunct treatments) during the trial period and the effect
of these treatments.
The occurrence of lymphedema, regardless of treatment
group allocation, is considered an 'adverse' event. If
lymphedema develops, women will be referred to the
Breast Cancer Nurse for referral to an appropriate special-
ist.
Data analysis
Sample size calculations
We will recruit 180 women, 90 to each of the two treat-
ment groups. This will give 80% power to detect as signif-
icant at the 2-sided 5% significance level a difference of 12
points (out of 100) for arm symptoms derived from the
BR23, based on our pilot data standard deviation of 25. In
addition, we have allowed for 20% mortality and loss to
follow-up. Based on our pilot data, we will also be able to
detect at least 10° difference in range of motion at the
shoulder and 5 N difference in shoulder strength.
Statistical analysis
Treatment group will be coded to enable blinded analysis,
which will be by "intention-to-treat". For the primary out-
come measure, the change from baseline score for arm
symptoms on the operated side derived from the BR23
will be determined. The mean change will be compared
between the two groups using Student's two-sample t-test.
Our secondary analyses will examine the effect of adjust-
ing for the stratifying factor (type of surgery) or any
important prognostic factors that show a clinically impor-
tant imbalance between groups. This will be done using
multiple linear regression, with the baseline arm symp-
toms score as a covariate and the final arm symptoms
score as the outcome variable.
For measures of strength, range of motion, and lymphe-
dema, the difference between the operated and non-oper-
ated side will be determined. These differences at 6
months will be compared using a two-sample t-test or dis-
tribution-free equivalent, as appropriate. For other aspects
of the quality of life score, the mean changes from base-
line will be compared between the two groups using Stu-
dent's two-sample t-test. As for the primary outcome,
multiple regression analyses will be used for all secondary
variables to adjust for covariates, including baseline differ-
ences.
Discussion
With more than 85% of women treated for breast cancer
surviving over 5 years, the long term sequelae of treatment
have become increasingly important [23]. Most women
are left with long-term symptoms affecting their arm and
shoulder [11]. Changes to surgical management for iden-
tification of the tumour have reduced the severity of long-
term sequelae but have not prevented them from occur-
ring. In fact, of women who undergo a sentinel node
biopsy, the 30% who then have an axillary node dissec-
tion in a two-step axillary operation are at greater risk of
developing arm morbidity than women who only
undergo axillary node clearance [5,24]. As long-term
symptoms compound the physical and psychological
trauma of the disease, preventing the resumption of a nor-BMC Cancer 2006, 6:273 http://www.biomedcentral.com/1471-2407/6/273
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mal physical and emotional life [3,4], it is important to
prevent their occurrence.
This randomized controlled trial was designed using fea-
tures that minimise bias [25]. For example, we have
included true randomisation, concealed allocation,
blinded measurement and data analysis, and analysis by
intention-to-treat. The nature of the treatments and out-
comes precludes blinding of treatment. However, bias will
be minimised by blinding subjects to the experimental
hypotheses. Thus, the findings from this study will dem-
onstrate the efficacy of an early intervention program
comprising progressive resistance training and prolonged
stretching.
The present proposal is to apply early, intensive exercise
for prevention of side-effects from surgery. The findings
from this study will enable the formulation of evidence-
based data on stretching and resistance training early fol-
lowing breast cancer surgery.
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